activated recombinant human factor VII

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Acquired Bleeding Disorder

Conditions

Acquired Bleeding Disorder, Trauma

Trial Timeline

Oct 6, 2004 → Nov 23, 2005

NCT ID

NCT00124293

About activated recombinant human factor VII

activated recombinant human factor VII is a pre-clinical stage product being developed by Novo Nordisk for Acquired Bleeding Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00124293. Target conditions include Acquired Bleeding Disorder, Trauma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01312636	Pre-clinical	Completed	Mar 1, 2011	Sep 1, 2014	Congenital Bleeding Disorder
NCT01285089	Pre-clinical	Completed	Dec 1, 2010	Oct 1, 2013	Acquired Bleeding Disorder
NCT01220141	Pre-clinical	Completed	Nov 1, 2010	Mar 1, 2015	Congenital Bleeding Disorder
NCT01234545	Pre-clinical	Completed	Oct 1, 2010	Apr 1, 2012	Congenital Bleeding Disorder
NCT00853086	Pre-clinical	Completed	Jan 1, 2008	Jun 1, 2011	Congenital Bleeding Disorder
NCT00323570	Phase 3	Withdrawn	May 1, 2006	Jun 1, 2007	Acquired Bleeding Disorder
NCT01562457	Phase 1	Completed	Nov 1, 2005	Apr 1, 2006	Congenital Bleeding Disorder
NCT00123591	Phase 2	Completed	Jan 1, 2005	May 1, 2006	Acquired Bleeding Disorder
NCT00124293	Pre-clinical	Completed	Oct 6, 2004	Nov 23, 2005	Acquired Bleeding Disorder
NCT00154427	Phase 2	Terminated	Aug 1, 2004	Nov 1, 2007	Acquired Bleeding Disorder
NCT00104455	Phase 1	Completed	Jun 1, 2004	Nov 1, 2004	Congenital Bleeding Disorder
NCT00154492	Phase 2	Completed	Apr 1, 2004	Aug 1, 2006	Acquired Bleeding Disorder
NCT00108758	Phase 2	Completed	Mar 1, 2004	Nov 1, 2005	Congenital Bleeding Disorder
NCT01476423	Pre-clinical	Completed	Jan 1, 2004	Oct 1, 2011	Congenital Bleeding Disorder
NCT00571584	Approved	Completed	Nov 1, 2002	Mar 1, 2004	Congenital Bleeding Disorder
NCT00426803	Phase 2	Completed	Aug 1, 2002	Jun 1, 2004	Acquired Bleeding Disorder
NCT01561352	Phase 2	Completed	Sep 1, 2001	Nov 1, 2003	Other Haemostasis Disorder

Competing Products

20 competing products in Acquired Bleeding Disorder

See all competitors

Product	Company	Stage	Hype Score
ONO-5046Na + ONO-5046Na	Ono Pharmaceutical	Phase 2	52
epoetin alfa	Johnson & Johnson	Phase 2	52
epoetin alfa	Johnson & Johnson	Phase 2	52
HRS-8427 + Meropenem	Jiangsu Hengrui Medicine	Phase 2	52
Ticagrelor + Placebo	AstraZeneca	Phase 2	52
IMI/REL FDC + PIP/TAZ FDC + Linezolid	Merck	Phase 3	77
Raltegravir + Atazanavir	Merck	Pre-clinical	23
Emicizumab Injection	Roche	Phase 2	52
PI + RTV + FTC/TDF + Stribild	Gilead Sciences	Phase 3	76
E/C/F/TDF + COBI + ATV + DRV + NRTI	Gilead Sciences	Phase 3	76
COBI + DRV + NRTIs	Gilead Sciences	Phase 3	76
Stribild	Gilead Sciences	Phase 3	76
ATV + DRV + Cobicistat + BR + F/TAF + LPV/r + Third Unboosted Drug + Cobicistat TOS + F/TAF TOS	Gilead Sciences	Phase 2/3	64
D/C/F/TAF + DRV + COBI + FTC/TDF + D/C/F/TAF Placebo + DRV Placebo + COBI Placebo + FTC/TDF Placebo	Gilead Sciences	Phase 2	51
Lopinavir 400 mg/ritonavir 100 mg + Efavirenz	Gilead Sciences	Approved	84
E/C/F/TAF + E/C/F/TAF (Low Dose)	Gilead Sciences	Phase 2/3	64
E/C/F/TDF + ATV + RTV + FTC/TDF + E/C/F/TDF Placebo + ATV Placebo + RTV Placebo + FTC/TDF Placebo + E/C/F/TAF	Gilead Sciences	Phase 3	76
NNRTI + FTC/TDF + Stribild	Gilead Sciences	Phase 3	76
E/C/F/TDF + E/C/F/TAF Placebo + E/C/F/TAF + E/C/F/TDF Placebo	Gilead Sciences	Phase 2	51
EVG + Background regimen	Gilead Sciences	Phase 2/3	64

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved

Liraglutide + SalineApproved

Hydrocortisone + PlaceboApproved

biphasic insulin aspart + insulin aspartApproved

Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved